| Controls | SSc patients | P | |
---|---|---|---|---|
Age [years] | 62 ± 11 | 61 ± 10 | 0.824 | |
Sex [n] | female | 10 | 17 | Â |
male | 12 | 2 | Â | |
BMI [kg/m2] |  | 25 ± 3 | 26 ± 5 | 0.714 |
LVM/BSA [g/m2] |  | 58 ± 11 | 54 ± 12 | 0.089 |
EDV/BSA [ml/m2] |  | 84 ± 12 | 76 ± 12 | 0.036* |
ESV/BSA [ml] |  | 32 ± 8 | 27 ± 7 | 0.069 |
CI [l/min/m2] |  | 3.2 ± 0.4 | 3.6 ± 0.6 | 0.014 |
Skin involvement [n] | diffuse | Â | 7 | Â |
limited | Â | 12 | Â | |
Disease duration [years] |  |  | 10 ± 6 |  |
Antibody [n] | ANA | Â | 6 | Â |
ACA | Â | 5 | Â | |
ARA | Â | 5 | Â | |
ATA | Â | 6 | Â | |
PAH [n] | Â | Â | 1 | Â |
VC % expected |  |  | 96 ± 12 |  |
DLCO % expected |  |  | 80 ± 19 |  |
VC % predicted / DLCO % predicted |  |  | 1.3 ± 0.3 |  |
Uric acid [μmol/L] |  |  | 262 ± 59 |  |
Telangiectasias [n] | Â | Â | 14 | Â |
Pitting scars [n] | Â | Â | 5 | Â |
Nailfold capillary density [loops/mm] |  |  | 5.0 ± 1.3 |  |
Skin score < 10 [n] |  |  | 18 |  |
Skin score 10–20 [n] |  |  | 1 |  |
Skin score > 20 [n] |  |  | 1 |  |
Nifedipine [n] | Â | Â | 12 | Â |
ERA [n] | Â | Â | 2 | Â |
PDE5I [n] | Â | Â | 5 | Â |